Phathom Pharmaceuticals Doubles Revenue but Faces Profitability Timing Test
Event summary
- Q1 2026 revenue surged 104% YoY to $58.3M, driven by VOQUEZNA prescriptions.
- Operating expenses fell 40% YoY to $61.8M, with cash usage at ~$15M.
- VOQUEZNA prescriptions hit 1.35M total, with 268K in Q1 alone (up 115% YoY).
- Company maintains FY 2026 guidance but delays profitability to Q3.
The big picture
Phathom's aggressive cost-cutting and sales force realignment reflect a pivot to GI dominance, but profitability timing hinges on maintaining prescription momentum. The $1B annual revenue target underscores the competitive stakes in gastroenterology, where VOQUEZNA faces established PPIs and emerging therapies.
What we're watching
- Revenue Momentum
- Whether April's prescription highs signal sustained growth after Q1's seasonal dip.
- Cost Discipline
- The pace at which expense reductions can offset revenue volatility before profitability kicks in.
- Pipeline Progress
- How Phase 2 trial results for eosinophilic esophagitis could expand VOQUEZNA's market potential.
Related topics